menu
    • menu

    Company profile for Dizal Pharmaceutical

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dizal Pharmaceutical is a global, science-oriented pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines. Dizal has built world's leading position in the translational science, new-drug molecular design and screening technology platform. It has accumulated extensive experience in the development of innovative therapies for the treatment of cancer, immunological diseases and ch...
    Dizal Pharmaceutical is a global, science-oriented pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines. Dizal has built world's leading position in the translational science, new-drug molecular design and screening technology platform. It has accumulated extensive experience in the development of innovative therapies for the treatment of cancer, immunological diseases and chronic kidney diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dizal PharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, Shanghai, China, 2...
    Telephone
    Telephone
    +86-21-61097800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.dizalpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dizal-pharma/life/48887300-daea-470e-8420-5be14b984685/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dizal Presents Lung Cancer Studies Portfolio at 2025 WCLC
    Dizal Presents Lung Cancer Studies Portfolio at 2025 WCLC

    09 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-showcases-robust-portfolio-of-lung-cancer-studies-at-2025-wclc-302550606.html

    PR NEWSWIRE
    09 Sep 2025
    Share Share
    Dizal Pharma`s Zegfrovy Receives Approval in US
    Dizal Pharma`s Zegfrovy Receives Approval in US

    02 Jul 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219839

    FDA
    02 Jul 2025
    Share Share
    Dizal's zegfrovy Gets FDA Approval for EGFR Exon 20 Mutations
    Dizal's zegfrovy Gets FDA Approval for EGFR Exon 20 Mutations

    02 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizals-zegfrovy-sunvozertinib-receives-fda-accelerated-approval-as-the-only-targeted-oral-treatment-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302497351.html

    PR NEWSWIRE
    02 Jul 2025
    Share Share
    Dizal Completes Phase 3 Enrollment of Sunvozertinib in NSCLC
    Dizal Completes Phase 3 Enrollment of Sunvozertinib in NSCLC

    19 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-completes-enrollment-for-its-phase-iii-pivotal-study-of-sunvozertinib-vs-platinum-doublet-in-treatment-naive-nsclc-patients-with-egfr-exon20-insertional-mutations-302486187.html

    PR NEWSWIRE
    19 Jun 2025
    Share Share
    Dizal Presents First-in-Class Therapies at EHA and ICML 2025
    Dizal Presents First-in-Class Therapies at EHA and ICML 2025

    12 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-showcases-two-first-in-class-therapies-in-hematologic-malignancies-at-eha-and-icml-2025-302480124.html

    PR NEWSWIRE
    12 Jun 2025
    Share Share
    Dizal to Advances in Hematologic Malignancies & Lung Cancer
    Dizal to Advances in Hematologic Malignancies & Lung Cancer

    26 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-to-highlight-its-portfolio-advances-in-hematologic-malignancies-and-lung-cancer-at-asco-2025-302465161.html

    PR NEWSWIRE
    26 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search